{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:19:30Z","timestamp":1780517970887,"version":"3.54.1"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5NU2RGH001913\u201005\u201000"],"award-info":[{"award-number":["5NU2RGH001913\u201005\u201000"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Risk Analysis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After the globally coordinated cessation of any serotype of oral poliovirus vaccine (OPV), some risks remain from undetected, existing homotypic OPV\u2010related transmission and\/or restarting transmission due to several possible reintroduction risks. The Global Polio Eradication Initiative (GPEI) coordinated global cessation of serotype 2\u2010containing OPV (OPV2) in 2016. Following OPV2 cessation, the GPEI and countries implemented activities to withdraw all the remaining trivalent OPV, which contains all three poliovirus serotypes (i.e., 1, 2, and 3), from the supply chain and replace it with bivalent OPV (containing only serotypes 1 and 3). However, as of early 2020, monovalent OPV2 use for outbreak response continues in many countries. In addition, outbreaks observed in 2019 demonstrated evidence of different types of risks than previously modeled. We briefly review the 2019 epidemiological experience with serotype 2 live poliovirus outbreaks and propose a new risk for unexpected OPV introduction for inclusion in global modeling of OPV cessation. Using an updated model of global poliovirus transmission and OPV evolution with and without consideration of this new risk, we explore the implications of the current global situation with respect to the likely need to restart preventive use of OPV2 in OPV\u2010using countries. Simulation results without this new risk suggest OPV2 restart will likely need to occur (81% of 100 iterations) to manage the polio endgame based on the GPEI performance to date with existing vaccine tools, and with the new risk of unexpected OPV introduction the expected OPV2 restart probability increases to 89%. Contingency planning requires new OPV2 bulk production, including genetically stabilized OPV2 strains.<\/jats:p>","DOI":"10.1111\/risa.13555","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T06:40:38Z","timestamp":1594104038000},"page":"320-328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Updated Characterization of Post\u2010OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart"],"prefix":"10.1111","volume":"41","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[{"name":"Kid Risk, Inc.  Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4818","authenticated-orcid":false,"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory, Diseases Centers for Disease Control and Prevention  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Cochi","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Center for Global Health Centers for Disease Control and Prevention  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Kovacs","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Center for Global Health Centers for Disease Control and Prevention  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G. F.","family":"Wassilak","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Center for Global Health Centers for Disease Control and Prevention  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-9147","authenticated-orcid":false,"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Kid Risk, Inc.  Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716677"},{"issue":"3","key":"e_1_2_6_3_1","first-page":"41","article-title":"Circulation of a type 2 vaccine\u2010derived poliovirus\u2013Egypt, 1982\u20131993","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6620a4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1536-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1537-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3074-0"},{"issue":"5","key":"e_1_2_6_8_1","first-page":"340","article-title":"Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation","volume":"7","author":"Duintjer Tebbens R. J.","year":"2016","journal-title":"Journal of Vaccines and Vaccination"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2018-0079"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023938"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.001"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00827.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12022"},{"issue":"389","key":"e_1_2_6_14_1","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","volume":"15","author":"Duintjer Tebbens R. J.","year":"2015","journal-title":"BMC Infectious Diseases"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1465-7"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1322514"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1506333"},{"key":"e_1_2_6_18_1","unstructured":"Global Polio Eradication Initiative. (2015).Global eradication of wild poliovirus type 2 declared. September 20 2015. Retrieved fromhttp:\/\/www.polioeradication.org\/mediaroom\/newsstories\/Global-eradication-of-wild-poliovirus-type-2-declared\/tabid\/526\/news\/1289\/Default.aspx"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu674"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13471"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13447"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068284"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.048"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1238"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu184"},{"key":"e_1_2_6_26_1","unstructured":"Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. (2017).World population prospects. The 2019 revision. Retrieved fromhttps:\/\/population.un.org\/wpp\/."},{"key":"e_1_2_6_27_1","unstructured":"PTI. (2018).Samples of oral polio vaccine found adulterated: MoS Health. Retrieved fromhttps:\/\/www.newindianexpress.com\/nation\/2018\/dec\/13\/samples-of-oral-polio-vaccine-found-adulterated-mos-health-1910936.html."},{"issue":"8","key":"e_1_2_6_28_1","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson K. M.","year":"2008","journal-title":"The Medscape Journal of Medicine"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.195"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix128"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1635463"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13484"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.013"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2012.01891.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31279-6"},{"key":"e_1_2_6_36_1","unstructured":"World Bank. (2019).World Bank analytical classifications \u2010 calendar year 2017 GNI per capita in US$ (Atlas methodology). Retrieved fromhttp:\/\/databank.worldbank.org\/data\/download\/site-content\/OGHIST.xls"},{"key":"e_1_2_6_37_1","unstructured":"World Health Assembly. (1988).Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Retrieved fromhttp:\/\/www.who.int\/csr\/ihr\/polioresolution4128en.pdf"},{"key":"e_1_2_6_38_1","unstructured":"World Health Assembly. (2008).Poliomyelitis: Mechanism for management of potential risks to eradication (resolution 61.1). Retrieved fromhttp:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA61-REC1\/A61_Rec1-part2-en.pdf"},{"key":"e_1_2_6_39_1","unstructured":"World Health Organization. (2019).World schedule as of 2018\/July\/11. Retrieved fromhttp:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules"},{"key":"e_1_2_6_40_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2019).Polio eradication and endgame strategic plan (2019\u20102023).Geneva; 2019. Report No: WHO\/POLIO\/19.04. Retrieved fromhttp:\/\/polioeradication.org\/wp-content\/uploads\/2019\/05\/polio-endgame-strategy-2019-2023.pdf"},{"key":"e_1_2_6_41_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2020a).Circulating vaccine\u2010derived poliovirus. Retrieved fromhttp:\/\/polioeradication.org\/wp-content\/uploads\/2020\/06\/weekly-polio-analyses-cVDPV-20200616.pdf"},{"key":"e_1_2_6_42_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2020b).Strategy for the response to type 2 circulating vaccine\u2010derived poliovirus 2020\u20132021: Addendum to the Polio eradication and endgame strategic plan (2019\u20102023).Geneva; 2020. Report No: WHO\/POLIO\/20.02. Retrieved fromhttp:\/\/polioeradication.org\/"}],"container-title":["Risk Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Frisa.13555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/risa.13555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/risa.13555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/risa.13555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:54:10Z","timestamp":1693684450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/risa.13555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/risa.13555"],"URL":"https:\/\/doi.org\/10.1111\/risa.13555","archive":["Portico"],"relation":{},"ISSN":["0272-4332","1539-6924"],"issn-type":[{"value":"0272-4332","type":"print"},{"value":"1539-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"2020-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}